StockNews.com assumed coverage on shares of OpGen (NASDAQ:OPGN – Free Report) in a research report report published on Monday morning. The firm issued a sell rating on the medical research company’s stock.
OpGen Trading Up 3.0 %
Shares of OPGN stock opened at $2.37 on Monday. OpGen has a twelve month low of $1.65 and a twelve month high of $38.40. The stock has a fifty day simple moving average of $2.74 and a two-hundred day simple moving average of $4.13.
OpGen (NASDAQ:OPGN – Get Free Report) last issued its earnings results on Monday, July 8th. The medical research company reported $0.21 earnings per share for the quarter. OpGen had a negative return on equity of 1,827.76% and a negative net margin of 997.34%. The business had revenue of $0.17 million during the quarter.
Institutional Investors Weigh In On OpGen
OpGen Company Profile
OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.
Featured Stories
- Five stocks we like better than OpGen
- How to invest in marijuana stocks in 7 steps
- Owens-Corning Stock: Good Value or Recession Red Flag?
- How to Invest in Insurance Companies: A Guide
- Datadog Exceeds Q2 Expectations, Solidifies Market Leadership
- Most active stocks: Dollar volume vs share volume
- Cybersecurity Stock Surges, Promising Double-Digit Gains
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.